Lol - I'll tell you what another risk is, acquiring another biotech and inheriting a fat pipeline that needs a lot of $$$ thrown at it despite already having some very eligible drug candidates. Was that savvy? Maybe, we'll see.
It has been straight carnage for the last while at IHL. We will have to wait and see whether we look back in the future at this raise being a savvy move.
